SCHEMBL6769615

SCHEMBL6769615

CCOC(=O)c1cnc2cc(NC(=O)c3ccccc3-c3ccc(SCC)cc3)ccc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.45
▸ MEN1 O00255 4/20 0.45
▸ KMT2A Q03164 4/20 0.45
▸ NPC1 O15118 4/20 0.45
▸ ALDH1A1 P00352 4/20 0.45
▸ MAPT P10636 4/20 0.45
▸ ABCB1 P08183 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ ABCG2 Q9UNQ0 1/20 0.45
▸ POLB P06746 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ GAA P10253 3/20 0.43
▸ MAOB P27338 4/20 0.42
▸ OPRL1 P41146 1/20 0.42
▸ LMNA P02545 3/20 0.40
▸ HDAC3 O15379 1/20 0.40
▸ HDAC4 P56524 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC7 Q8WUI4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7687336 0.90 MAOB (0.52) RAB9AMEN1KMT2ANPC1ALDH1A1
SCHEMBL6766186 0.90 MEN1 (0.51) RAB9AMEN1KMT2ANPC1ALDH1A1
SCHEMBL6769585 0.89 OPRL1 (0.44) RAB9AMEN1KMT2AMAPTGAA
SCHEMBL7686490 0.89 MAOB (0.49) RAB9AMEN1KMT2ANPC1ALDH1A1
SCHEMBL6769382 0.89 MAPT (0.49) RAB9AMEN1KMT2ANPC1ALDH1A1
SCHEMBL6765884 0.88 RAB9A (0.48) RAB9AMEN1KMT2ANPC1ALDH1A1
SCHEMBL6770450 0.87 MTTP (0.48) RAB9AMEN1KMT2ANPC1ALDH1A1
SCHEMBL6770414 0.87 RAB9A (0.46) RAB9AMEN1KMT2ANPC1ALDH1A1
SCHEMBL6776420 0.87 RAB9A (0.48) RAB9AMEN1KMT2ANPC1ALDH1A1
SCHEMBL6769278 0.86 MAPT (0.49) RAB9AMEN1KMT2ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713489-B2 TREATMENT OF ATHEROSCLEROSIS, OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERLIPOPROTEINEMIA, HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDEMIA, HYPOALPHALIPOPROTEINEMIA, PANCREATITIS, MYOCARDIAL INFARCTION, STROKE, RESTENOSIS, OR SYNDROME X PFIZER INC 2004-03-30 — — US disclosed
US-20020132806-A1 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B RUGGERI ROGER (US) 2002-09-19 — — US disclosed
US-6369075-B1 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B PFIZER, INC. 2002-04-09 — — US disclosed
EP-1099701-A1 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B Pfizer Products Inc. (US) 2001-05-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132806-A1 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B APOB, CETP, PNLIP RAB9A 1539/4885MEN1 4036/4885KMT2A 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback